One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The Partnership to Fight Infectious Disease has put out a timely notice about support for vaccines. Forty-five minutes before ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

“Awareness initiatives like Thyroid Awareness Month play a crucial role in promoting early screening and intervention,” the ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...